Bristol Myers buys out cell therapy partner 2seventy bio
Bristol Myers Squibb will acquire its CAR-T cell therapy collaborator 2seventy bio for $286 million in cash, the companies said late Monday evening. BMS and 2seventy have been longtime teammates on Abecma, the multiple myeloma ...
Bristol Myers Squibb will acquire its CAR-T cell therapy collaborator 2seventy bio for $286 million in cash, the companies said late Monday evening.
BMS and 2seventy have been longtime teammates on Abecma, the multiple myeloma ...
